Shehab Mohamed: TP53 Mutations and Outcomes in Myeloproliferative Neoplasms
Shehab Mohamed, Hematologist at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in eJHaem, adding:
“Here we go!
We share our newly published systematic review in eJHaem!
Our study, ‘Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review,’ synthesizes the available evidence on the prevalence, allelic characteristics, and clinical outcomes of TP53-mutated MPNs.
Across 11 retrospective cohorts comprising 603 patients, TP53 mutations were enriched in advanced disease, with particularly poor outcomes in myelofibrosis and accelerated/blast-phase MPN.
Importantly, the prognostic impact of single-hit versus multi-hit TP53 appeared strongly dependent on disease phase.
Key findings included a pooled TP53 mutation prevalence of 3% overall, rising to 10% in MF or AP/BP-MPN cohorts, a mean VAF of 37.5%, and only 16% allo-HCT utilization.
Median overall survival in AP/BP-MPN was approximately 4.5–6 months.
A sincere thank you to the entire team and all our collaborators for their valuable contributions, dedication, and teamwork that made this study possible.”
Title: Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review
Authors: Mahmood Aldapt, Rasha Kaddoura, Ahmed O. Saleh, Mostafa Najim, Ahmad Salem, Abdulrahman F. Al-Mashdali, Bassam Muthanna, Ruba Adel Aweer, Marrita Rabadi, Shehab F. Mohamed
Other posts featuring Shehab Mohamed on Hemostasis Today.
-
Sep 24, 2026, 13:41Mahmoud Samir Bayomi: Raise ITP Awareness and Improve Patient Care
-
Sep 24, 2026, 12:56Maria Helena Parrinello: A New Score for Chronic GvHD Risk Assessment at the SIE Congress
-
Sep 24, 2026, 12:34Francesca Palandri: Is There Still a Place for Splenectomy in ITP in the Modern Era?
-
Sep 24, 2026, 12:15Cedric Hermans: RPTH Illustrated Review on Von Willebrand Disease
-
Sep 24, 2026, 11:48Factor XII Inhibition and the Future of Contact Pathway Targeting
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure
-
Sep 24, 2026, 06:33Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access